Background: To date, there are no guidelines recommending a specific prophylactic
prophylaxis could further reduce the lengths of hospitalizations. 2, 3 On the other hand, in cardiac surgery, one meta-analysis showed that a prophylaxis duration of ≤24 h post-operation was inferior compared to longer regimes, without any additional benefit when prolonging over 48 h. 4 However, TAVR is much less invasive than SAVR and hardly impairs the integrity of the skin, and reduces the risk of pneumonia associated with a sternotomy and hypothermia.
The incidence of infective endocarditis (IE) after TAVR is low, with reported numbers between 0.5 5 and 1.1% 6 according to some studies.
The prevalence of IE patients who had received a TAVR seems to be similar to that of patients who underwent SAVR. 7 Some risk factors in TAVR patients have been discussed, such as non-sterile environment of catheterization laboratories and failure to administer antibiotic prophylaxis before TAVR. Nonetheless, the impact of different prophylactic regimens on the incidence of postinterventional endocarditis remains unclear.
On the other hand, while the influence of various complications on prolonged hospitalization have been extensively studied, [8] [9] [10] it is not yet known, if a certain antibiotic prophylactic regimen is directly associated with post TAVR complications and duration of hospitalization. This also includes the risk of antibiotic related diarrhea or Clostridium difficile infection. 11, 12 Therefore, the aim of this study was to evaluate different antibiotic prophylactic treatments on post TAVR complications and duration of hospitalization. A change in institutional standard operating procedure from mandatory 3-day cefuroxime prophylaxis to 1-day was used to retrospectively analyze its influence on outcome parameters.
| METHODS
After excluding all patients with periprocedural death (up to 72 h after TAVR) and patients with signs of infection or inflammation prior to TAVR, a total of 450 patients undergoing elective TAVR between All patients were diagnosed with severe symptomatic aortic stenosis with an orifice area <1 cm 2 after echocardiographic and/or invasive assessment. Decisions about patient selection, appropriate access route, and device size were made in a multidisciplinary heart team setting. All patients were informed about specific risks and alternatives of TAVR and gave informed written consent to TAVR and pre-and post-interventional monitoring (data collection). The study protocol was approved by the local ethics committee (S-299/2015). A mandatory cardiac and vascular computed tomography scan using a 256-slice Brilliance iCT scanner (Philips Healthcare) was performed in all patients prior to TAVI as previously described. 13 Table 2 summarizes main and secondary clinical outcomes.
However, the incidence of diarrhea was significantly higher among patients in the 3-day group. There was no difference on the day of onset (3-day Cefuroxime 4 ± 3 days vs 1-day Cefuroxime 4 ± 3; P = 0.93) or duration of diarrhea (3-day Cefuroxime 3 ± 3 days vs 1-day Cefuroxime 3 ± 3; P = 0.54) between groups. Clostridium difficile infection also occurred significantly more often among patients with 3-day treatment compared to 1-day prophylaxis. Within surviving patients, no endocarditis was registered after 1 year follow-up.
Incidence of intra-hospital infection (until 7 days after TAVR) did not significantly differ between groups. One patient had cholecystitis, another presented a catheter-associated infection, 22 patients developed pneumonia and 16 patients developed urinary tract infection. Sepsis occurred in five patients. Type of infections were similarly distributed among both groups (P = 0.29). Intra-hospital infections were significantly associated with the incidence of diarrhea (P < 0.0001) and were also a significant independent predictor (Odds ratio (OR) for incidence of diarrhea: 4.4; Confidence interval (CI) 95%:
2.3-8.4, P < 0.001; OR for Cefuroxime regimen: 1.8, CI 95%: 1.1-2.8, P = 0.017) after logistic regression considering incidence of intrahospital infections and cefuroxime regimen group as independent variables. Intra-hospital infections were not significantly associated with Clostridium difficile infections after Fisher's exact test (P = 1.00).
There were no cases of conversion to open surgery, coronary obstruction, annular rupture, ventricular perforation, or valve thrombosis. Complication rates after TAVR, including major vascular complications, major bleeding complications, disabling stroke, AKI, new PPI, than mild PVR and intra-hospital overall mortality were identical between both groups.
We further studied possible independent predictors of overall mortality, total hospitalization stay and ICU stay using regression analysis. A summary of results from regression models are displayed in Table 3 . Incidence of diarrhea (OR: 5.8; CI 95%: 1.6-21.7; P < 0.01), intra-hospital infections (OR: 5.4; CI 95%: 1.5-19.1; P < 0.01) and stroke (OR: 11.9; CI 95%: 1.6-86., P < 0.01) were found to be independent risk factors of intra-hospital overall mortality in a multivariate logistic regression model including major vascular complications, major bleeding, more than mild PVR, new PPI, disabling stroke and STS-Score as independent variables. Clostridium difficile infections (P < 0.001), incidence of diarrhea (P < 0.001), and intrahospital infections (P < 0.001) were strong predictors of longer total hospital stay, along with new PPI (P = 0.01) in a multivariate logistic regression. Moreover, occurrence of diarrhea (P < 0.001), intrahospital infections (P < 0.01), incidence of intra-hospital overallmortality (P < 0.001) and STS-Score (P = 0.048) were found to be independent risk factors for a longer ICU stay. prophylaxis were changed from mandatory 3 days to 1 day. We used this defined change in our SOP to build two different intentionto-treat groups that allow a retrospective analysis. Since both groups are very similar in most parameters, and no other relevant concepts were changed in our TAVR program, this study design is the nearest we can get to a randomized trial despite its retrospective design. In this study we compared the duration of hospitalization, incidence of diarrhea and Clostridium difficile infections, incidence of intra-hospital infections between the last 225 patients under the recommendation of 3-day cefuroxime prophylaxis and the first 225 patients under the recommendation of a shorter 1-day cefuroxime regimen.
A shorter cefuroxime regimen resulted in significantly lower incidence of both diarrhea and Clostridium difficile infections. This is in line with the pathophysiology of Clostridium difficle infections, whereas its colonization of the intestinal tract after depletion of the normal flora leads to antibiotic-associated diarrhea and even pseudomembranous colitis. 15 Also, gastrointestinal disturbances are a well described side-effect associated with cephalosporine therapy.
Interestingly, there were no registered cases of IE of the THV after 1 year follow-up. This may be due to the low incidence of this lifethreatening event, despite described endocarditis rates between 0.5% and 1.1% after 6 months to 1 year of follow-up. 5, 6, 16 The incidence of overall intra-hospital infections remained similar after shortening the recommended prophylaxis to 1 day. Three-day cefuroxime regimen did not avoid the occurrence of a specific infection, as the rates of sepsis, pneumonia, and urinary tract infections remained similar.
While a shorter antibiotic prophylaxis did not have an impact on hospital duration, Clostridium difficile infections, incidence of diarrhea and intra-hospital infections after TAVR were strong predictors of a longer hospitalization course. A significant association between intrahospital infections and diarrhea could be confirmed in this study, but infection and a 3-day cefuroxime regimen were found to be risk factors of diarrhea independently from one another in a multivariate logistic regression model. Moreover, 1-day Cefuroxime regimen showed similar 30-day mortality rates compared to a longer regimen. Again, intra-hospital infections and occurrence of diarrhea were found to be independent predictors of mortality. Clostridium difficile infections were not associated with higher mortality rates.
This study is mainly limited by its non-randomized design.
Consequently, as our two populations are not contemporaneous, Evolut R and Lotus valves were significantly more often implanted under the 1-day cefuroxime recommendation. Nonetheless, our study did not show either significant association between lower complication rates after TAVR or better outcomes in the studied main endpoints favoring these two THVs. In addition to this, we have two distinct intention-to-treat groups showing consistent homogeneity in the distribution of baseline characteristics, procedural outcomes, and complications after TAVR that avoid possible bias in the interpretation of the results.
| CONCLUSION
One day of antibiotic prophylaxis is preferable compared to three days.
1-day cefuroxime regimen did not increase the incidence of intrahospital infections or 1 year incidence of infective endocarditis, and was not associated with longer hospitalization. 3-day cefuroxime prophylaxis even posed a significantly increased risk of developing diarrhea and Clostridium difficile infections. This finding could have a significant impact on the choice of a periprocedural antibiotic regimen in transvascular aortic valve replacements on daily practice. Further studies with longer follow-up periods are needed to confirm these findings.
